BioNanoScience, Год журнала: 2024, Номер 15(1)
Опубликована: Дек. 2, 2024
Язык: Английский
BioNanoScience, Год журнала: 2024, Номер 15(1)
Опубликована: Дек. 2, 2024
Язык: Английский
Journal of Drug Delivery Science and Technology, Год журнала: 2025, Номер unknown, С. 106853 - 106853
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0Cancer Medicine, Год журнала: 2024, Номер 13(15)
Опубликована: Авг. 1, 2024
Abstract Background Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. Objective This study aimed investigate anticancer efficacy conjugated system, consisting doxorubicin cisplatin (Dox‐Cis), encapsulated within niosomes modified with MUC‐1 aptamers enhance biocompatibility target specific cancer cells. Methods The chemical structure Dox‐Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) Liquid Chromatography Quadrupole Time‐of‐Flight Mass Spectrometry (LC‐Q‐TOF/MS). zeta potential morphological parameters niosomal vesicles were determined through Dynamic Light Scattering (DLS) Transmission Electron Microscopy (TEM). In vitro assessments cell viability apoptosis conducted positive HeLa cells negative U87 Results findings confirmed successful conjugation Dox Cis niosomes. Nio/Dox‐Cis/MUC‐1 formulation demonstrated enhanced compared individual drugs their unencapsulated combination in both lines. Notably, exhibited greater effectiveness (38.503 ± 1.407) than (46.653 1.297). Conclusion underscores as promising strategy for treatment, particularly platforms that facilitate delivery approach could lead more personalized therapies.
Язык: Английский
Процитировано
3BioNanoScience, Год журнала: 2024, Номер 15(1)
Опубликована: Дек. 2, 2024
Язык: Английский
Процитировано
3